Lyell Immunopharma

Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies for cancer. The firm operates from its headquarters in South San Francisco, with additional research and manufacturing facilities in Seattle and Bothell, Washington. Its fully integrated model combines in-house scientific research, therapy development, and proprietary manufacturing to advance a pipeline of product candidates. The firm's pipeline is anchored by two clinical-stage programs. Rondecabtagene autoleucel (ronde-cel) is under evaluation in two pivotal clinical trials for patients with aggressive large B-cell lymphoma. A second candidate, LYL273, is in Phase 1 clinical development for patients with refractory metastatic colorectal cancer. Lyell's strategy targets both hematologic malignancies and solid tumors, leveraging novel CAR constructs and T-cell enhancement technologies designed to produce more potent and durable cancer cell killing than first-generation therapies. Lyell's structural backbone is the LyFE Manufacturing Center in Bothell, Washington. At full staffing and capacity, the facility can manufacture more than 1,200 patient CAR T-cell products annually — a scale intended to support both late-stage clinical trials and potential commercial launches. The company maintains additional offices in Seattle's Fairview Avenue corridor and operates its own supply chain, giving it end-to-end control over the production of each cell therapy. Unlike many biotech firms that outsource manufacturing, Lyell's ownership of its production facility is its primary structural differentiator. This vertical integration is designed to mitigate supply chain risk, accelerate the incorporation of scientific innovations into products, and maintain consistent quality standards across trials and potential commercial scale-up.